Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Medical professional performs COVID-19 test using the Abbot BinaxNOW rapid test in December 2020 in Livingston, Montana. Photo: William Campbell/Getty Images

As many Americans prepare to travel and see loved ones ahead of Thanksgiving, developers and sellers of rapid at-home COVID-19 tests say they are prepared to meet an expected spike in demand for their products.

The big picture: The U.S. has been slower to embrace rapid at-home COVID-19 testing than Europe as regulatory hurdles helped make the tests scarce and overpriced. But the Biden administration has recently allocated billions of dollars to buy millions of rapid at-home COVID-19 tests to increase supply.

Between the lines: Experts predict that the holiday season, as well as new vaccine mandates for federal contractors and certain employees, will lead to a spike in demand that stresses the supply chain, the Washington Post reported.

  • Several developers of rapid tests, as well as pharmacies that sell them, told Axios that they feel prepared to meet consumer demand.
  • The Kaiser Family Foundation's Lindsey Dawson noted on Twitter that an experimental search for over-the-counter COVID-19 rapid tests produced dozens more tests in November than a similar search in September.

State of play: Abbott, which produces the BinaxNow rapid test, told Axios that it has scaled up its manufacturing operation to produce more than 50 million tests per month, and will be "widely available" through the holidays.

  • Quidel said that it has a "more than adequate" supply of rapid tests and is on track to be producing 50 million of its QuickVue rapid tests monthly by the end of the year.
  • Cue Health, which just debuted the consumer version of its rapid test last week, told Axios that they are "prepared to meet the demand we're seeing from new and existing customers."
  • An Ellume spokesperson told Axios that the company "stands ready" to meet an increased demand for its tests.

A Quidel spokesperson noted that the company anticipates a possible "continued rise in cases through Thanksgiving, especially in the Northeast and Midwest."

  • Vault Health, whose test is available via DoorDash, told Axios that it has seen demand increasing nationwide, with slightly higher rates, "in places like Texas, Florida, New Mexico."

Representatives from CVS and Walmart maintained that their inventories of over-the-counter rapid tests for COVID-19 are sufficient to meet the rising holiday demand.

  • A spokesperson for CVS said they have a stocked inventory and "are prepared to meet our customers’ needs as we enter the holiday season."
  • Walmart has increased its in-store and online inventory in recent weeks and is continuing to work with suppliers to meet demand, a spokesperson said.

The bottom line: A Biden administration official told Axios that the U.S. at-home rapid testing capacity has grown, "nearly three-fold since our September investments to accelerate production."

  • "Ahead of the holiday season, tests are much more readily available at retailers across the country and online thanks to these actions."

Go deeper

Axios-Ipsos poll: Shrugging off Omicron

Expand chart
Data: Axios/Ipsos poll; Note: The last question only includes 589 employed respondents; Chart: Kavya Beheraj/Axios

Most Americans aren't willing to make big changes in their behavior to minimize the risk from the Omicron variant, like avoiding indoor restaurant dining or cancelling their holiday travel plans, according to a new Axios-Ipsos poll.

The big picture: The poll found support for some broader public responses, including one — travel bans aimed at people from other countries — that was widely supported by people across the political spectrum. But it found that Americans are only willing to do so much on their own.

Updated 16 hours ago - Politics & Policy

Omicron dashboard

Illustration: Shoshana Gordon/Axios

  1. Health: Americans shrug off Omicron, Axios-Ipsos poll finds — CDC director says number of U.S. Omicron cases "likely to rise."
  2. Vaccines: Omicron gives a shot to boosters — U.S. announces $400M for global COVID vaccine distribution — Vaccine mandates lose steam in the U.S. while Europe doubles down.
  3. States: Gov. Hochul will order some NY hospitals to halt elective surgeries — Nevada to impose insurance surcharge on unvaccinated state workers.
  4. World: EU drug regulator backs mixing COVID vaccines — Poor global equity likely in COVID pill access — CDC raises travel advisories for France, Portugal to highest level amid COVID surge.
  5. Variant tracker: Where different strains are spreading.
16 hours ago - Health

EU drug regulator backs mixing COVID vaccines

A health worker administers the COVID-19 vaccine at a center outside Rome's Termini railway station in Rome, Italy, on Dec. 3. Photo: Alessia Pierdomenico/Bloomberg via Getty Images

The European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC) announced on Tuesday their support for mixing different COVID-19 vaccines in initial vaccinations and booster campaigns.

Why it matters: The announcement comes as several European countries struggle to combat recent surges in COVID-19 cases and amid concerns over the Omicron variant.